USFDA grants priority review to Merck’s NDA for HIF-2α inhibitor Belzutifan

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.